Post-Chemotherapy Retroperitoneal Teratoma in Nonseminomatous Germ Cell Tumors: Do Predictive Factors Exist? Results From a National Multicenter Study

被引:14
作者
Dusaud, Marie [1 ]
Malavaud, Bernard [2 ]
Bayoud, Younes [1 ]
Sebe, Philippe [3 ]
Hoepffner, Jean Luc [4 ]
Salomon, Laurent [5 ]
Houlgatte, Alain [6 ]
Pignot, Geraldine [7 ]
Rigaud, Jerome [8 ]
Flechon, Aude [9 ]
Pfister, Christian [10 ]
Roupret, Morgan [11 ]
Soulie, Michel [2 ]
Mejean, Arnaud [12 ]
Durand, Xavier [1 ]
机构
[1] Hop Instruct Armees Begin, Dept Urol, St Mande, France
[2] Univ Hosp Toulouse, Toulouse, France
[3] Hop Tenon, Paris, France
[4] Clin St Augustin Bordeaux, Bordeaux, France
[5] Hop Henri Mondor, Creteil, France
[6] Hop Instruct Armees Val de Grace, Paris, France
[7] Univ Hosp Kremlin Bietre, Paris, France
[8] Jules Verne Clin Nantes, Nantes, France
[9] Ctr Leon Berard, Lyon, France
[10] Ctr Hosp Univ Rouen, Rouen, France
[11] Hop La Pitie Salpetriere, Paris, France
[12] Hop Europeen Georges Pompidou, Paris, France
关键词
testicular neoplasm; retroperitoneal lymph node dissection; teratoma; chemotherapy; LYMPH-NODE DISSECTION; TESTICULAR CANCER; EUROPEAN CONSENSUS; TESTIS CANCER; CHEMOTHERAPY; HISTOLOGY; MEN; DIAGNOSIS; NECROSIS; SURGERY;
D O I
10.1002/jso.24464
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and Objectives: To identify predictive preoperative factors of the presence of teratoma in retroperitoneal lymph node dissection specimens. Methods: We performed a 20 years multicenter retrospective analysis of all patients who underwent retroperitoneal lymph node dissection for residual masses after chemotherapy (PC-RPLND). Patients had undergone PC-RPLND after chemotherapy for advanced testicular cancer. The histologic components of the primary tumor were compared with those of the residual masses using logistic regression. Results: A total of 469 NSGCT patients underwent PC-RPLND (complete data available for 211). By PC-RPLND, necrosis was found in 84 cases, teratoma in 102 cases, and viable tumor in 25 cases. The univariate and multivariate analyses showed that teratoma (P = 0.001 and P = 0.002, respectively) and yolk sac tumor (P = 0.009 and P = 0.035, respectively) in orchiectomy specimens were statistically significant predictors of the presence of teratoma in retroperitoneal lymph nodes. Conclusions: PC-RPLND is the standard treatment for any supracentimetric residual lesion. This procedure is associated with a high morbidity, and almost half patients are overtreated. The presence of teratoma and yolk sac tumor in the orchiectomy specimen were independent significant predictors of teratoma in retroperitoneal masses. (C) 2016 Wiley Periodicals, Inc
引用
收藏
页码:992 / 996
页数:5
相关论文
共 23 条
  • [1] Prediction of necrosis after chemotherapy of advanced germ cell tumors: Results of a prospective multicenter trial of the German Testicular Cancer Study Group
    Albers, P
    Weissbach, L
    Krege, S
    Kliesch, S
    Hartmann, M
    Heidenreich, A
    Walz, P
    Kuczyk, M
    Fimmers, R
    [J]. JOURNAL OF UROLOGY, 2004, 171 (05) : 1835 - 1838
  • [2] Guidelines on Testicular Cancer: 2015 Update
    Albers, Peter
    Albrecht, Walter
    Algaba, Ferran
    Bokemeyer, Carsten
    Cohn-Cedermark, Gabriella
    Fizazi, Karim
    Horwich, Alan
    Laguna, Maria Pilar
    Nicolai, Nicola
    Oldenburg, Jan
    [J]. EUROPEAN UROLOGY, 2015, 68 (06) : 1054 - 1068
  • [3] [Anonymous], 2009, TNM CLASSIFICATION M
  • [4] Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in post-chemotherapy nonseminomatous testis cancer
    Beck, SDW
    Foster, RS
    Bihrle, R
    Ulbright, T
    Koch, MO
    Wahle, GR
    Einhorn, LH
    Donohue, JP
    [J]. JOURNAL OF UROLOGY, 2002, 168 (04) : 1402 - 1404
  • [5] Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer
    Beyer, J.
    Albers, P.
    Altena, R.
    Aparicio, J.
    Bokemeyer, C.
    Busch, J.
    Cathomas, R.
    Cavallin-Stahl, E.
    Clarke, N. W.
    Classen, J.
    Cohn-Cedermark, G.
    Dahl, A. A.
    Daugaard, G.
    De Giorgi, U.
    De Santis, M.
    De Wit, M.
    De Wit, R.
    Dieckmann, K. P.
    Fenner, M.
    Fizazi, K.
    Flechon, A.
    Fossa, S. D.
    Germa Lluch, J. R.
    Gietema, J. A.
    Gillessen, S.
    Giwercman, A.
    Hartmann, J. T.
    Heidenreich, A.
    Hentrich, M.
    Honecker, F.
    Horwich, A.
    Huddart, R. A.
    Kliesch, S.
    Kollmannsberger, C.
    Krege, S.
    Laguna, M. P.
    Looijenga, L. H. J.
    Lorch, A.
    Lotz, J. P.
    Mayer, F.
    Necchi, A.
    Nicolai, N.
    Nuver, J.
    Oechsle, K.
    Oldenburg, J.
    Oosterhuis, J. W.
    Powles, T.
    Rajpert-De Meyts, E.
    Rick, O.
    Rosti, G.
    [J]. ANNALS OF ONCOLOGY, 2013, 24 (04) : 878 - 888
  • [6] Improved clinical outcome in recent years for men with metastatic nonseminomatous germ cell tumors
    Carver, Brett S.
    Serio, Angel M.
    Bajorin, Dean
    Motzer, Robert J.
    Stasi, Jason
    Bosl, George J.
    Vickers, Andrew J.
    Sheinfeld, Joel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (35) : 5603 - 5608
  • [7] Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma
    Carver, Brett S.
    Shayegan, Bobby
    Serio, Angel
    Motzer, Robert J.
    Bosl, George J.
    Sheinfeld, Joel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (09) : 1033 - 1037
  • [8] Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymph node dissection
    Carver, BS
    Bianco, FJ
    Shayegan, B
    Vickers, A
    Motzer, RJ
    Bosl, GJ
    Sheinfeld, J
    [J]. JOURNAL OF UROLOGY, 2006, 176 (01) : 100 - 103
  • [9] Contemporary Management of Postchemotherapy Testis Cancer
    Daneshmand, Siamak
    Albers, Peter
    Fossa, Sophie Dorothea
    Heidenreich, Axel
    Kollmannsberger, Christian
    Krege, Susan
    Nichols, Craig
    Oldenburg, Jan
    Wood, Lori
    [J]. EUROPEAN UROLOGY, 2012, 62 (05) : 867 - 876
  • [10] Chemotherapy for teratoma with malignant transformation
    Donadio, AC
    Motzer, RJ
    Bajorin, DF
    Kantoff, PW
    Sheinfeld, J
    Houldsworth, J
    Chaganti, RSK
    Bosl, GJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (23) : 4285 - 4291